endpoints and indications for the older population
play

Endpoints And Indications For The Older Population William J. - PowerPoint PPT Presentation

Endpoints And Indications For The Older Population William J. Evans, Head Muscle Metabolism Discovery Unit, Metabolic Pathways & Cardiovascular Therapy Area Outline Functional Endpoints and Geriatrics Sarcopenia and reduced mobility as


  1. Endpoints And Indications For The Older Population William J. Evans, Head Muscle Metabolism Discovery Unit, Metabolic Pathways & Cardiovascular Therapy Area

  2. Outline Functional Endpoints and Geriatrics Sarcopenia and reduced mobility as indications Geriatric Indications Consideration of Older Patients Aging Effects – Loss of skeletal muscle (sarcopenia), changing body composition, reduced blood volume/kg weight, impaired regulation of appetite and thirst, decreased GH, IGF1, Testosterone, Estradiol Geriatric Patients – Multiple chronic diseases, poly-pharmacy, frailty, inflammation EMA Workshop on Geriatrics

  3. Short Physical Performance Battery Functional measurement for trials that include elderly people – Developed at the National Institute on Aging (NIA) for use in the Established Population for the Epidemiologic Studies of the Elderly (EPESE) – Timed standing balance (up to 10 seconds) Side-by-side stand Semi-tandem stand Tandem stand – Timed 4-meter walk (habitual gait speed) – Chair rise Single Timed multiple (5) chair rises Six minute walk distance: validated in clinical populations, difficult to perform by health care provider EMA Workshop on Geriatrics

  4. SPPB Development and Scoring 4 m Walking 5 Chair Stands Balance (time) (time) SCORE Side-by-Side 0 Unable Unable 0-9 s 1 Semitandem > 7.5 s > 16.6 s 0-9 s 2 Tandem 5.4-7.5 s 13.7-16.6 s 0-2 s 3 Tandem 4.1-5.3 s 11.2-13.6 s 3-9 s 4 Tandem < 4.1 s < 11.2 s 10 s

  5. 2- -Year Mortality and Nursing Home Admission Year Mortality and Nursing Home Admission 2 According to Baseline SPPB (EPESE) According to Baseline SPPB (EPESE) Guralnik JM, Simonsick EM, Ferrucci L et al. Guralnik JM, Simonsick EM, Ferrucci L et al. - - J. Gerontol 1994 J. Gerontol 1994 25 25 12 12 20 20 NH Adimission per 100 Persons/Years NH Adimission per 100 Persons/Years Deaths per 100 Persons/Years Deaths per 100 Persons/Years 15 15 8 8 10 10 4 4 5 5 0 0 0 0 0 1 2 3 4 5 6 7 8 9 10 10 11 11 12 12 0 0 1 1 2 2 3 3 4 4 5 5 6 6 7 7 8 8 9 10 9 10 11 11 12 12 0 1 2 3 4 5 6 7 8 9 SPPB Score SPPB Score SPPB Score SPPB Score

  6. EMA Workshop on Geriatrics

  7. Walking Speed Predicts Mortality Percentage who Survived 1.00 Walking Speed >0.8 m/sec 0.75 Cancer Walking Speed < 0.8 m/sec 0.50 0 2 4 6 Follow-up (years) Ble & Ferrucci (unpublis EMA Workshop on Geriatrics

  8. Tzankoff and Norris, Effect of muscle mass decrease on age- related BMR changes, J Appl Physiol 43: 1001, 1977 Basal Oxygen Consumption Urinary Creatinine (mg/24 hrs) (L/min, STPD)

  9. Sarcopenia Age related loss of skeletal muscle mass and function Evans, W What is Sarcopenia, J. Gerontol. , 50A: 5-8, 1995. Evans, W Sarcopenia and age-related changes in body composition and functional capacity, J. Nutr ., 123: 465- 468, 1993. EMA Workshop on Geriatrics

  10. Sarcopenia: An undiagnosed condition in older adults. Current consensus definition JAMDA, 2011 “Sarcopenia is the age-associated loss of skeletal muscle mass and function. Sarcopenia is a complex syndrome that is associated with muscle mass loss alone or in conjunction with increased fat mass. The causes of sarcopenia are multifactorial and can include disuse, changing endocrine function, chronic diseases, inflammation, insulin resistance and nutritional deficiencies.” “Sarcopenia represents a major cause of disability and increased health costs in older persons. It is very common, but like most geriatrics syndromes, seldom recognized by physicians” Diagnosis of sarcopenia: – Habitual gait speed of < 1 m/sec – Objectively measured low muscle mass Appendicular lean mass (DEXA) – < 7.23 kg/m 2 (Men) – < 5.67 kg/m 2 (Women) EMA Workshop on Geriatrics

  11. Prevalence of sarcopenia, Women JAGS, 50:889-896, 2002 - NHANES III % Class I: SMI within 1-2 SD of young adult Class II: >2 SD of young adult

  12. Prevalence of sarcopenia, Men JAGS, 50:889-896, 2002 - NHANES III % %

  13. Etiology of Frailty (Fried model ) EMA Workshop on Geriatrics

  14. Body Composition in post-menopausal women by BMI Lean Fat EMA Workshop on Geriatrics

  15. Sarcopenic Obesity Int J Obesity 28: 234, 2004 “Obesity was strongly associated with self-reported physical functional health, equivalent to being 11 years older for men and 16 y for women .” “In clinical practice, BMI may be considered as a simple to obtain marker of the risk of functional impairment in the elderly.” EMA Workshop on Geriatrics

  16. Intentional and unintentional weight loss increase bone loss and hip fracture risk in older women, Ensrud, et al, J Am Geriatr Soc 51: 1740-1747, 2003 6,785 women > 65 yrs examined over an average of 5.7 yrs r r y y / / D D Wt. Loss > 5% from M M baseline B B n – Asked about intention to n i i lose weight ∆ ∆ – Wt. Loss: 78.3 ± 5.3 % % – Wt. Stable: 76.4 ± 4.7 – Wt. Gain: 75.4 ± 4.2

  17. Undesirable side effect of weight loss in elderly people “Older women who experience weight loss in later years have increased rates of hip-bone loss and a two-fold greater risk of subsequent hip fracture, irrespective of current weight or intention to lose weight.” “These findings indicate that even voluntary weight loss in overweight elderly women increases hip fracture risk.”

  18. �������� ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ Fatty acid Muscle Body and Insulin Strength Bone ����������� oxidation mass visceral fat resistance functional density ���������� capacity ������������������������������� ↓ ↓ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↓ ↓ ↓ Muscle Cortisol Insulin Fatty acid Strength Bone protein sensitivity resistance oxidation density synthesis – + – ↑ ↑ ↑ ↑ Nitrogen ↑ ↑ ↑ ↑ Intramuscular + loss triglyceride ↑ ↑ ↑ ↑ Dietary protein Osteoporosis needs ��������������� ↓ ↓ ↓ ↓ Muscle + mass ������� Fall Bone Fracture

  19. Effect of 10 days of bed rest on skeletal muscle in healthy older adults, JAMA 297: 2007 10 days complete bedrest 12 subjects, 67 ± 5 years Eucaloric diet, 0.8g protein/kg/d Body composition (DEXA) Fractional Synthetic Rate of muscle protein – 24-h infusion of 13 C 6 -phenylalanine, vastus lateralis biopsy pre-post infusion EMA Workshop on Geriatrics

  20. ������������������������������ Effect of 10 days of bed rest on skeletal muscle in healthy older adults, JAMA 297: 2007 40% reduction in rate of muscle protein synthesis 250 Young Control Elderly 28 Days 10 Days Change in lean leg mass (g) 0 -250 (n=12) -500 2% -750 total lean leg mass -1000 -1500 9% total lean leg mass -2000 Whole body muscle loss: >2kg (~5% total lean mass) EMA Workshop on Geriatrics

  21. Effects of bed rest on physical activity and VO 2max -15.1 ± ± 4.3% change ± ± -1% reduction/year with normal aging 10 d bedrest = 15 years of aging * 20% reduction in physical activity *P = 0.017 Functional impact of ten days bed rest in healthy older adults, J. Gerontol. Med Sci . 63: 1076-1081, 2008.

  22. Unmet Need for Medicines in Geriatrics Opportunities: Frailty Concerns about criteria for diagnosis - Sarcopenia and Sarcopenic Obesity Consensus on diagnostic criteria Fat is a powerful predictor of late-life dysfunction Deconditioning/Mobility Limitations Caused by illness, depression, fear of falling, loss of muscle mass Anorexia of Aging/Involuntary Weight loss Strong mortality risk, increased risk < 24 BMI Consequences of Hospitalization Rapid and progressive loss of physical and cognitive function Elderly people often receive different level of care and have different needs – nutritional support, pain medication, reduced immune function and increased risk of infection, orthostatic intolerance EMA Workshop on Geriatrics

Recommend


More recommend